Multimodality Imaging Features of a Misleading Sacral Giant Cell Tumor in 18F-FDG PET/CT, Bone Scan, and MRI.


Journal

Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109

Informations de publication

Date de publication:
Oct 2020
Historique:
pubmed: 1 7 2020
medline: 11 11 2020
entrez: 1 7 2020
Statut: ppublish

Résumé

We report the case of an asymptomatic 66-year-old woman referred for initial staging of an invasive ductal breast carcinoma. Initial workup incidentally revealed a bone tumor of right sacral wing corresponding to a giant cell tumor (GCT). We present the imaging characteristics of GCT on Tc-HDP bone scan (doughnut sign), F-FDG PET/CT (intense and heterogeneous uptake of a prominent geographic lytic lesion with partial rupture of cortical), and MRI (hyposignal with gadolinium enhancement on T1-weighted images and heterogeneous hypersignal on T2-weighted images). GCT is a benign but locally aggressive primary bone tumor, constituting a pitfall and diagnostic challenge.

Identifiants

pubmed: 32604109
doi: 10.1097/RLU.0000000000003148
pii: 00003072-202010000-00014
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

800-801

Références

Amanatullah DF, Clark TR, Lopez MJ, et al. Giant cell tumor of bone. Orthopedics. 2014;37:112–120.
Chakarun CJ, Forrester DM, Gottsegen CJ, et al. Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics. 2013;33:197–211.
Mavrogenis AF, Igoumenou VG, Megaloikonomos PD, et al. Giant cell tumor of bone revisited. SICOT J. 2017;3:54.
Muheremu A, Ma Y, Huang Z, et al. Diagnosing giant cell tumor of the bone using positron emission tomography/computed tomography: a retrospective study of 20 patients from a single center. Oncol Lett. 2017;14:1985–1988.
Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology. 2001;219:774–777.
Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, et al. 18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med. 2004;45:1528–1535.
Park HL, Yoo IR, Lee Y, et al. Giant cell tumor of the rib: two cases of F-18 FDG PET/CT findings. Nucl Med Mol Imaging. 2017;51:182–185.
Montgomery C, Couch C, Emory CL, et al. Giant cell tumor of bone: review of current literature, evaluation, and treatment options. J Knee Surg. 2019;32:331–336.

Auteurs

Sebastien Dejust (S)

From the Unité de Médecine Nucléaire.

Pascaline Jallerat (P)

From the Unité de Médecine Nucléaire.

Pauline Soibinet-Oudot (P)

Oncologie Médicale, Institut Jean Godinot.

Christelle Jouannaud (C)

Oncologie Médicale, Institut Jean Godinot.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH